Thyroxine therapy after thyroid surgery for low-risk cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of thyroxine replacement therapy in patients who have undergone lobectomy for low-risk papillary thyroid carcinoma. The study aims to control Thyroid Stimulating Hormone (TSH) levels to improve outcomes and reduce recurrence rates. Participants will be closely monitored for disease-free status following treatment. The trial focuses on patients with specific criteria, including tumor size and absence of metastasis, to ensure a targeted approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Age 18-70 years old, ECOG score 0-2;
* (2) Patients with the maximum diameter of unilateral thyroid nodules ≤4.0cm by ultrasound, papillary thyroid carcinoma diagnosed by preoperative cytology (Bethesda grade VI) or intraoperative freezing, and planned to undergo thyroid lobectomy;
* (3) No clinical lymph node metastasis (cN0);No extrathyroidal extension, and the number of pathological lymph node micrometastasis (\<0.2cm) was ≤5.
* (4) no serious medical diseases and major organ dysfunction, such as blood routine, liver, kidney, heart, lung function; No previous history of other head and neck malignancies, no history of neck radiation, no history of deep neck surgery (skin mass excision except clinical);
* (5) Fully understand this study, have the ability to complete treatment, have follow-up conditions and voluntarily sign informed consent.

Exclusion Criteria:

* (1) History of malignancy in other sites (previous or simultaneous), excluding curable non-melanoma skin cancer and cervical carcinoma in situ;
* (2) The contralateral thyroid nodules were evaluated by preoperative ultrasound, and the patients with suspicious nodules who underwent fine-needle aspiration cytology and could not confirm the benign or malignant nodules (Bethesda grade I, III-V) were excluded.
* (3) Cervical lymph node metastasis was evaluated before surgery. Cytological aspiration and Tg eluent determination were performed on suspicious lymph nodes. If cytology was negative and Tg eluent was not higher than the normal range, it was not considered as exclusion criteria. The patients who were sent for intraoperative examination and showed metastasis were excluded.
* (4) cytological aspiration or intraoperative freezing suspected non-papillary thyroid carcinoma (follicular carcinoma, medullary carcinoma, poorly differentiated or undifferentiated carcinoma) or high-risk subtypes of papillary thyroid carcinoma (high cell type);
* (5) pregnant or lactating women；
* (6) A history of drug use or drug abuse within the past 1 year;
* (7) Participants who had participated in other clinical trials within 4 weeks before enrollment;
* (8) The patient is unable to accept the preservation of the contralateral gland or cannot cooperate with subsequent thyroid hormone replacement therapy.
* (9) The investigator assesses subjects who are unsuitable for the trial for other reasons, or who are not expected to complete the study.

Where it's running

• Cancer Hospital, Chinese Academy of Medical Science
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: jie liu
• Email: liujie10-11@vip.163.com
• Phone: +861087787180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prophylactic central neck dissection for low-risk papillary thyroid cancer

  This study is testing if a specific type of surgery can help people with low-risk thyroid cancer live longer and have fewer recurrences of the disease.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06082180

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• WeChat-supported neck exercises after thyroidectomy

  A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07707401

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.